{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-23-043545","form_type":"8-K","ticker":"ABVC","cik":"0001173313","company_name":"ABVC BIOPHARMA, INC.","filed_at":"2023-05-26T23:59:59+00:00","discovered_at":"2026-05-14T18:03:38.143394+00:00","generated_at":"2026-06-14T12:34:16.882326+00:00","sec_items":["3.01"],"event_type":"regulatory","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"ABVC BioPharma receives Nasdaq deficiency letter for low stockholders' equity","bullets":["Stockholders' equity of $1.73M as of March 31, 2023, below Nasdaq's $2.5M minimum.","Company has until July 10, 2023 to submit compliance plan; possible extension to Dec 11, 2023.","No immediate effect on trading; common stock continues on Nasdaq under symbol ABVC."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-23-043545","json":"https://secwatch.observer/filing/0001213900-23-043545.json","markdown":"https://secwatch.observer/filing/0001213900-23-043545.md","text":"https://secwatch.observer/filing/0001213900-23-043545.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1173313/000121390023043545/0001213900-23-043545-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1173313/000121390023043545/ea179215-8k_abvcbio.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-14T12:34:16.882326+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"c4287189ba1a27133696e1860466ce2c57c45dd1","claim":"ABVC BIOPHARMA, INC. received a nasdaq deficiency notice notice regarding stockholders equity (rules 5550(b)(1)).","evidence_excerpt":"Market. Nasdaq Listing Rule 5550(b)(1) requires listed companies to maintain stockholders’ equity of at least $2,500,000, and the Company’s stockholders’ equity was $1,734,507 as of March 31, 2023. In accordance with Nasdaq rules, the Company has 45 calendar days, or until July 10, 2023, to submit a plan to regain compliance. If the plan is accepted,","evidence_source":"SEC 8-K Item 3.01","evidence_url":"https://www.sec.gov/Archives/edgar/data/1173313/000121390023043545/0001213900-23-043545-index.htm","confidence":0.95,"family_label":"Listing & Compliance Notices","details":[{"label":"Exchange","value":"nasdaq"},{"label":"Notice","value":"deficiency notice"},{"label":"Deficiency","value":"stockholders equity"},{"label":"Rules","value":"5550(b)(1)"}],"fact_type":"exchange_compliance_notice"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}